Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(10)60268-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Tale of 2 Countries: Implementation of the Cold Chain Equipment Optimization Platform in Guinea and Kenya.
Glob Health Sci Pract
October 2022
JSI Research & Training Institute, Inc., Arlington, VA, USA.
In 2016, the Gavi Cold Chain Equipment Optimization Platform (CCEOP) was approved and launched in recognition of the fact that functional cold chain equipment (CCE) is essential to strengthening vaccine supply chains and ultimately achieving Gavi's immunization equity and coverage goals. Through CCEOP, Gavi committed to investing US$250 million between 2016 and 2021 to commission CCE in more than 63,000 facilities to upgrade and expand their CCE footprint while stimulating the market to provide affordable, technologically advanced, and accessible equipment. We present case studies from Guinea and Kenya, both of which received CCEOP support, that highlight 2 ways for countries to prioritize investments and implement activities through a large funding and support mechanism.
View Article and Find Full Text PDFSeizing market shaping opportunities for vaccine cold chain equipment.
Vaccine
April 2017
McKinsey & Company, Place de Cornavin 7, Geneva 1201, Switzerland. Electronic address:
Gavi, the Vaccine Alliance, supports immunisation programmes in eligible countries to reach children with lifesaving vaccines. Dramatic improvement in the scale and performance of current cold chain systems is required to extend the reach of immunisation services - especially for children living in remote locations - to advance progress towards full vaccine coverage. Achieving these improvements will require a healthier market for cold chain equipment where the products meet user needs, are sustainably priced, and are available in sufficient quantities to meet demand.
View Article and Find Full Text PDFExploring the Case for a Global Alliance for Medical Diagnostics Initiative.
Diagnostics (Basel)
January 2017
International Clinical Research Center, Department of Global Health, University of Washington, Seattle, WA 98195, USA.
In recent years, the private and public sectors have increased investments in medical diagnostics for low- and middle-income countries (LMICs). Despite these investments, numerous barriers prevent the adoption of existing diagnostics and discourage the development and introduction of new diagnostics in LMICs. In the late 1990s, the global vaccine community had similar challenges, as vaccine coverage rates stagnated and the introduction of new vaccines was viewed as a distraction to delivering existing vaccines.
View Article and Find Full Text PDFCosts of vaccine programs across 94 low- and middle-income countries.
Vaccine
May 2015
International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 855 N. Wolfe St., Suite 600, Baltimore, MD 21205, USA; Public Health Computational and Operational Research (PHICOR) Group, Johns Hopkins Bloomberg, School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA. Electronic address:
While new mechanisms such as advance market commitments and co-financing policies of the GAVI Alliance are allowing low- and middle-income countries to gain access to vaccines faster than ever, understanding the full scope of vaccine program costs is essential to ensure adequate resource mobilization. This costing analysis examines the vaccine costs, supply chain costs, and service delivery costs of immunization programs for routine immunization and for supplemental immunization activities (SIAs) for vaccines related to 18 antigens in 94 countries across the decade, 2011-2020. Vaccine costs were calculated using GAVI price forecasts for GAVI-eligible countries, and assumptions from the PAHO Revolving Fund and UNICEF for middle-income countries not supported by the GAVI Alliance.
View Article and Find Full Text PDFMaking new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
Lancet
November 2011
Chatham House Centre on Global Health Security, The Royal Institute of International Affairs, London, UK.
Mechanisms to increase access to health products are varied and controversial. Two innovative mechanisms have been used to accelerate the development of low-price supply lines for conjugate vaccines. The Meningitis Vaccine Project is a so-called push mechanism that facilitated technology transfer to an Indian company to establish capacity to manufacture a vaccine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!